Janice Lu, MD, PhD
Professor, Medicine (Hematology and Oncology)
Research Program
- Translational Research in Malignancy (TRIM)
Cancer-Focused Research
I am a Clinical Investigator specializing in the management of breast cancer. My research primarily centers on developmental therapeutics and translational aspects of breast cancer, with a focus on immunotherapy, antibody drug conjugates and cell therapies, and investigating new and cutting-edge treatment for unmet need. I serve on various committees within I-SPY Consortium and NRG for breast cancer drugs development and innovative trials. 
I have made contributions to the development of new agents for HER2-positive breast cancer. This includes leading an NSABP study, participating in a T-DM1 trial, and spearheading the development of a novel HER2 agent. I serve as PI of an investigator-initiated trial: Phase Ib clinical study at USC, utilizing anti-NY-ESO-1 TCR engineered T cells in triple negative breast cancer. I also serve as the Vice-Chair of the NRG Oncology Immunotherapy Subcommittee, responsible for leading the initiatives for immunotherapy projects within the NRG Oncology Cooperative Group.